BioCentury
ARTICLE | Product R&D

Hemorrhaging targets

An ASH abstract preview by target, indication, modality and more

November 17, 2016 11:02 PM UTC

An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new targets to watch, a growing role for nucleic acid based therapies, and a continued expansion of cell type subsets beyond the commonly used B cells and Tregs.

This year’s meeting, which takes place December 3-6 in San Diego, has a heavy emphasis on hematological malignancies, which account for more than 75% of the preclinical abstracts. ...